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Inflammation and the generation of reactive oxygen species (ROS) have been implicated
in the initiation and progression of atherosclerosis. Although C-reactive protein (CRP) has
traditionally been considered to be a biomarker of inflammation, recent in vitro and in vivo
studies have provided evidence that CRP, itself, exerts pro-thrombotic effects on vascular
cells and may thus play a critical role in the development of atherothrombosis. Of par-
ticular importance is that CRP interacts with Fcγ receptors on cells of the vascular wall
giving rise to the release of pro-thrombotic factors.The present review focuses on distinct
sources of CRP-mediated ROS generation as well as the pivotal role of ROS in CRP-induced
tissue factor expression. These studies provide considerable insight into the role of the
oxidative mechanisms in CRP-mediated stimulation of pro-thrombotic factors and activa-
tion of platelets. Collectively, the available data provide strong support for ROS playing an
important intermediary role in the relationship between CRP and atherothrombosis.
Keywords: atherothrombosis, C-reactive protein, platelet, reactive oxygen species, vascular cells
INTRODUCTION
Mounting evidence indicates that atherosclerosis is a chronic
inflammatory process, and further, that inflammation plays an
important role in acute coronary syndromes (Davì and Patrono,
2007). Considerable data exists to support a causative role for reac-
tive oxygen species (ROS) in these inflammatory states. Specifi-
cally, ROS generation triggers a cascade of events including inflam-
mation,endothelial cell injury, blood coagulation,and thrombosis.
Understanding the exact role played by ROS in vascular inflamma-
tion, however, is made difficult by observations that the generation
of ROS appears to occur via a number of differing cell types and
through varied mechanisms. Further, there appears to be a com-
plex interplay between ROS and other inflammatory mediators,
such as C-reactive protein (CRP) (Zeller and Sullivan, 1992; Irani,
2000; Venugopal et al., 2003; Qamirani et al., 2005; Ryu et al., 2007;
Singh et al., 2007; Wu et al., 2008), whereby ROS not only induce
production of the inflammatory mediator, but are produced in
response to the mediator. Thus a vicious cycle can lead to the
development of chronic inflammation.
Biologically active CRP, an acute phase reactant and member
of the pentraxin family of plasma proteins, is composed of five
identical subunits each with a molecular weight of approximately
23,000 kDa. The pentamer circulates as a discoid and annular-
shaped complex. Recent studies, however, have shown that the
pentamer can locally dissociate to give biological active monomers
(mCRP) although evidence for circulating mCRP is not currently
available (Bharadwaj et al., 1999; Khreiss et al., 2004). The site of
synthesis of CRP is predominately hepatic although the localiza-
tion of mRNA for CRP in tissues and atheromatous plaque has
been used to suggest that local production could contribute to
inflammation in vascular disease.
C-reactive protein is an accepted serum marker for inflamma-
tion (Järvisalo et al., 2002; Danesh et al., 2004; Emerging Risk
Factors Collaboration et al., 2010). Further, a number of stud-
ies have confirmed that an elevated CRP is associated with an
increased risk of ischemic vascular events, such as myocardial
infarction (Zebrack et al., 2002; Khreiss et al., 2005; Singh et al.,
2006). CRP has been detected in atherosclerotic lesions in human
coronary arteries both at the protein and mRNA levels (Heinrich
et al., 1995; Hak et al., 1999; Willeit et al., 2000; Blackburn et al.,
2001). However, although the role of CRP has been argued to be
involved in the development of atherosclerotic plaque size (Paul
et al., 2004; Hirschfield et al., 2005; Trion et al., 2005), it is also well
correlated with activation of the blood coagulation system and
subsequently increasing the risk of thrombosis (Danenberg et al.,
2003; Bisoendial et al., 2005). This may provide an explanation for
why some studies using plaque size as an endpoint measure do not
find a pathophysiological role of CRP.
As stated above, ROS generation plays a significant role in
inflammatory processes, and the subsequent activation of pro-
thrombotic factors and platelets by inflammatory mediators may
also be a critical component of atherothrombosis. However, the
molecular mechanisms responsible for inflammation-mediated
disease processes are not clear, especially as it occurs in CRP-
related atherothrombosis. Thus, the present manuscript will focus
on studies examining CRP-mediated molecular mechanisms that
link ROS generation to the activation of both thrombotic risk fac-
tors and platelets and subsequent vascular dysfunction. We also
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highlight the importance of ROS in linking CRP to the develop-
ment of atherothrombosis. Specifically, we discuss evidence for (1)
the role of ROS in atherosclerosis; (2) the role of CRP in vascular
inflammation and atherosclerosis; (3) involvement of CRP in ROS
generation and atherosclerosis; and (4) ROS and CRP in platelet
activation and thrombus formation. Finally, we provide an inte-
grated model linking CRP to the downstream generation of ROS
via the FcyR and pro-atherothrombotic events in vascular cells
including endothelial and smooth muscle cells, macrophages, and
platelets. Therefore, we conclude that CRP is not simply a marker
of inflammation, but also directly contributes to the pathogenesis
of atherothrombosis.
ROLE OF ROS IN ATHEROSCLEROSIS
Considerable support exists for overproduction of ROS playing a
pivotal role in the development of CVD and that this may occur
through a number of mechanisms (Bouloumie et al., 1999; Sorescu
et al., 2002; Guzik et al., 2006; Lee and Hirani, 2006). For exam-
ple, superoxide anion, a major component of endogenous ROS,
has been observed to accumulate in the walls of human coro-
nary arteries with atherosclerosis. Further, it is well-known that
elevated production of ROS is linked to the over expression of
pro-inflammatory mediators, which themselves play a critical role
in early steps of atherogenesis (Sorescu et al., 2002; Guzik et al.,
2006; Lee and Hirani, 2006). ROS also contribute to the mod-
ification of protein structure and function. Thus, oxidized-LDL
(ox-LDL) plays a key role in the development of atherogenesis in
different cell types, including endothelial cells (Huang et al., 1999),
vascular smooth muscle cells (VSMC) (Kataoka et al., 2001), and
monocytes (Xu et al., 1999). Importantly, the presence of LDL
oxidation can be observed in situ by the localization of specific ox-
LDL antibodies within atherosclerotic lesions (Palinski et al., 1989;
Ylä-Herttuala et al., 1989). In addition, oxidative stress alters the
balance of vasodilator and vasoconstrictor mechanisms. Consis-
tent with this, oxidative stress decreases NO bioavailability due to
the breakdown of NO by ROS and the formation of highly reactive
and damaging nitrosyl species that lead to endothelial dysfunc-
tion and eventually the development of atherosclerotic changes
(Singh et al., 2007; Bonomini et al., 2008; Giacco and Brownlee,
2010; Hulsmans and Holvoet, 2010). Further, studies have shown
that ROS can increase ET-1 production in cultured endothelial
(Davì and Patrono, 2007) and VSMC (Irani, 2000), although, ROS
does not appear to be the stimulus for ET-1 release during acute
stress in vivo (Venugopal et al., 2003). Similarly, hydrogen per-
oxide (H2O2) has been shown to participate in the increased
in vivo synthesis of constrictor prostaglandins (Singh et al., 2007).
Collectively, the above information provides strong support for
ROS contributing to the development of atherosclerosis and fur-
ther information can be found in a number of recent reviews
(Bonomini et al., 2008; Giacco and Brownlee, 2010; Hulsmans and
Holvoet, 2010).
ROLE OF CRP IN VASCULAR INFLAMMATION AND
ATHEROSCLEROSIS
C-reactive protein is traditionally considered as the prototypic
marker of inflammation and is one of the strongest predictors of
cardiovascular events that are currently available (Järvisalo et al.,
2002). Accumulating evidence has demonstrated that CRP is both
present in atherosclerotic plaques and that it may play an impor-
tant role in promoting atherogenesis through the regulation of
expression and release of inflammatory cytokines (Khreiss et al.,
2005; Singh et al., 2006). Plasma CRP levels correlate poorly with
atherosclerotic plaque burden in humans (Zebrack et al., 2002).
In addition to its production by the liver (Gabay and Kushner,
1999), CRP has been reported to be produced by macrophages
and smooth muscle cells (Dong and Wright, 1996; Kobayashi et al.,
2003; Khera et al., 2006) and mRNA for CRP has been detected
within human atherosclerotic plaque further supporting local syn-
thesis (Jabs et al., 2003). However, doubt still exists as to whether
CRP in the atherosclerotic lesions originates from the circulation
or is locally synthesized by the vascular cells (Dong and Wright,
1996; Jabs et al., 2003; Kobayashi et al., 2003; Khera et al., 2006).
Sun et al. (2005) using established animal atherosclerosis models,
i.e., both cholesterol-fed and Watanabe heritable hyperlipidemic
rabbits, have shown that CRP found in the atherosclerotic lesions
was essentially derived from the circulation rather than synthesized
de novo by vascular cells.
C-reactive protein has been shown to induce pro-inflammatory
effects through overproduction of several pro-inflammatory
mediators including monocyte chemoattractant protein-1 (MCP-
1), intercellular cell adhesion molecule (ICAM), and vascular cell
adhesion molecule-1 (VCAM-1). This CRP-dependent response
has been observed in a number of human types such as endothelial
cells, VSMC, and macrophages (Pasceri et al., 2000, 2001; Devaraj
and Jialal, 2011). Additionally, CD40 ligand (CD40L) is expressed
on the surface of platelets, T lymphocytes, and endothelial cells
(Schönbeck and Libby, 2001; Lin et al., 2004) There is evidence
that the CD40L level is a strong predictor of cardiovascular risk.
The pro-inflammatory effects of CRP via CD40–CD40L signal-
ing pathways also involved in the pathogenesis of atherosclerosis
(Lin et al., 2004). Collectively these studies are consistent with the
proposition that CRP may exert its pro-atherogenic effects through
enhanced expression of pro-inflammatory mediators including
both chemokines and adhesion molecules. Despite this, it contin-
ues to be debated whether CRP plays a causal role in the develop-
ment of atherosclerosis, or is simply an important clinical marker
of inflammation and cardiovascular risk (Zacho et al., 2008).
Recent experiments, crossing human CRP-transgenic mice into
ApoE-knockout mice, demonstrated that CRP promotes, inhibits,
or has no effect on atherosclerotic plaque growth (Paul et al., 2004;
Hirschfield et al., 2005; Trion et al., 2005). The reason responsi-
ble for this discrepancy remains to be identified, but human CRP
was present in the developing atheromas, including human and
CRP-transgenic mice vascular lesions (Paul et al., 2004). Although
there is apparent argument regarding the role of CRP in the risk of
atherosclerosis, the positive results support the need to explore the
exact mechanisms by which CRP might trigger the development
of atherosclerotic lesions. Recent human studies demonstrated
that elevated CRP levels more likely is a marker for the extent
of atherosclerosis or for the inflammatory activity of atheroscle-
rotic plaques, and effectively exclude that genetically elevated CRP
cause CHD (Nordestgaard and Zacho, 2009).
The Justification for the Use of Statins in Primary Preven-
tion: an Intervention Trial Evaluating Rosuvastatin (JUPITER)
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trial (Ridker et al., 2008, 2010), have reported the role of CRP
as a biomarker of risk for cardiovascular disease and estab-
lished it as a means of monitoring the impact of cholesterol-
lowering therapy, not only in people with known risks, but also
in asymptomatic individuals previously considered at average
risk for myocardial infarction and stroke. The study emphasizes
the importance of inflammation in cardiovascular disease and
could result in changes to recommended cardio-protective prac-
tices and patient management. The effectiveness of statins in the
JUPITER trial lower CRP levels as well as cholesterol, however,
it is still argued whether statin drugs reduces the incidence of
major cardiovascular events (Hingorani et al., 2009; Ridker et al.,
2010).
A number of prospective epidemiologic studies have consis-
tently demonstrated a strong association between CRP concentra-
tions measured in initially healthy individuals and the risk of a first
CHD event (Hingorani et al., 2009). There is considerable interest
in whether CRP has a causal role in CHD whether CRP is merely
a marker of underlying atherosclerosis (Pepys, 2008; Zacho et al.,
2008). These arguments support the hypothesis that CRP increases
the risk of CHD, not by promoting atherosclerotic plaque size, but
rather by activating the blood coagulation system and increasing
the risk of thrombosis.
ROS AND CRP IN ATHEROSCLEROSIS
As outlined above ROS overproduction is believed to be involved
in the signal transduction processes leading to vascular inflam-
mation and ultimately the progression of atherosclerosis (Basta
et al., 2005; Thomas et al., 2008). Oxidative stress results in cell
dysfunction and death. Major enzymes responsible for ROS gen-
eration in vascular cells include xanthine oxidase, cytochrome
P-450, nitric oxide synthase (NOS), and NAD(P)H oxidase
(Bonomini et al., 2008; Giacco and Brownlee, 2010; Hulsmans
and Holvoet, 2010). CRP stimulates ROS production by vari-
ous vascular cell types in vitro, including endothelial, smooth
muscle, and monocyte/macrophages (Zeller and Sullivan, 1992;
Irani, 2000; Venugopal et al., 2003; Qamirani et al., 2005; Ryu
et al., 2007; Singh et al., 2007; Wu et al., 2008). CRP was co-
localized with p22phox by VSMC, both in vitro and in vivo, an
essential component of NADPH oxidase, which is an impor-
tant source of ROS in vasculature (Kobayashi et al., 2003). CRP
could activate NAD(P)H oxidase and upregulate ROS produc-
tion in both endothelial cells and macrophages (Singh et al.,
2005; Zhao et al., 2011). CRP promotes superoxide anion release
from endothelial cells and reduces NO bioavailability by involve-
ment of p22phox and p47phox (Singh et al., 2007). In porcine
coronary arterioles, the treatment of CRP significantly increased
NAD(P)H oxidase activity and this was mediated via the acti-
vation of mitogen activated protein kinase p38MAPK (Qami-
rani et al., 2005). Furthermore, accumulation of Ox-LDL in
atherosclerotic lesions is a well-known event in the develop-
ment of atherosclerosis. CRP promotes Ox-LDL uptake and
matrix metalloproteinase induction through Fcγreceptor from
macrophage and endothelial cells (Singh et al., 2008; Schwedler
et al., 2009). Collectively, these findings support the suggestion that
intracellular ROS generation is associated with CRP-associated
atherosclerosis.
ROS AND CRP IN PLATELET ACTIVATION AND THROMBUS
FORMATION
In response to blood vessel injury, platelets accumulate at the site
of damage to form a clot. ROS play a key role in this process pro-
moting platelet aggregation and thrombosis (Ikeda et al., 1994).
Consistent with this role, antioxidants have been shown to reduce
platelet aggregation (Przyklenk and Kloner,1993). In addition,NO
insufficiency, combined with ROS overproduction, predisposes
to a platelet-dependent pro-thrombotic disorder by decreasing
NO-dependent vasorelaxation and increasing platelet aggregation
(Freedman et al., 1996; Keaney et al., 1996). FcγRIIa and FcγRIII
are expressed on platelet, and ligand-binding of these receptors can
directly activate platelets resulting in platelet aggregation. CRP has
been reported to bind to the family of FcγRs in platelets including
FcγRIIa and FcγRIII (Järvisalo et al., 2002). Previous studies have
demonstrated that CRP inhibits platelet aggregation induced by a
variety of agonists, including thrombin, platelet aggregating fac-
tor (PAF), and immunoglobulin (Fiedel and Gewurz, 1976; Filep
et al., 1991; Cheryk et al., 1996; Filep, 2009). CRP also promotes
platelet adhesion to endothelial cells and monocytes (Yaron et al.,
2006; Danenberg et al., 2007), which is linked to causation of
thrombosis. A previous study showed that stimulation of human
neutrophils, monocytes, and platelets by modified CRP express a
neoantigenic specificity (Potempa et al., 1988). Recently, Molins
et al. (2008) showed that there was a facilitation of thrombus
growth after platelet stimulation with monomeric CRP. The con-
formation of CRP (i.e., monomeric vs. pentameric) conceivably
plays a role in the regulation of platelet aggregation (Bharadwaj
et al., 1999; Khreiss et al., 2004). Activated platelets have been
also shown to directly contribute to the conversion of pentameric
CRP (pCRP) to the monomeric form (mCRP) (Devaraj et al.,
2003, 2009; Eisenhardt et al., 2009). In fact, the conformation of
CRP plays a different role in activation of molecular mechanisms.
pCRP has been reported to inhibit insulin activation of endothelial
NOS via FcγRIIB and Src homology 2 domain-containing inosi-
tol 5′-phosphate (SHIP-1), and activation of nuclear factor κB in
monocytes,which may leads to endothelial dysfunction and release
of pro-inflammatory cytokines (Filep, 2009; Tanigaki et al., 2009).
In addition to platelet-mediated actions,CRP has been linked to
thrombosis, via direct effects on plasminogen activator inhibitor-
1 (PAI-1), tissue plasminogen activator, and tissue factor activity
in vascular cells (Danenberg et al., 2003; Singh et al., 2005; Ryu
et al., 2007; Wu et al., 2008). CRP induces superoxide anion
release tissue factor (Wang et al., 2005). PAI-1 is a marker of
impaired fibrinolysis and atherothrombosis. CRP induces PAI-
1 mRNA, antigen, and activity in endothelial cells, suggesting
that CRP may be an atherothrombotic agent CRP induces PAI-1
mRNA, antigen, and activity in ECs (Devaraj et al., 2003). Pre-
treatment with antioxidants such as pyrrolidine dithiocarbamate
(PDTC), N -acetylcysteine (NAC) resulted in a marked attenua-
tion of CRP-mediated tissue factor activity in human VSMC (Wu
et al., 2008). Furthermore, CRP-induced FcγRIIa activation trig-
gers NADPH oxidase 4 activation and subsequent ROS generation,
which demonstrated the direct relationship between CRP and ROS
via FcγR (Ryu et al., 2007; Zhao et al., 2011). In vivo, mice carrying
a human CRP transgene have been shown to exhibit accelerated
thrombosis and increased intimal hyperplasia following vascular
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FIGURE 1 |The role of ROS in CRP and atherothrombosis. CRP promotes
the generation of reactive oxidant species (ROS) through binding to ECs,
platelets, monocytes, and VSMC via specific Fcγ receptors. Several potential
mechanisms are involved, including the inhibition of endothelial nitric oxide
synthase, activation nuclear factor κB in monocytes, and release of extrinsic
and intrinsic coagulation factors in vascular smooth muscle cells (VSMC).
These molecules and cell–cell interactions, in turns, may contribute to
endothelial dysfunction, release of cytokines. Ox-LDL, Oxidized low-density
lipoprotein; VSMC, Vascular smooth muscle cell; MCP-1, monocyte
chemoattractant protein-1; ICAM-1, intercellular adhesion molecule-1;
VCAM-1, vascular adhesion molecule-1; TF, tissue factor; TFPI, tissue factor
pathway inhibitor; PAI-1, plasminogen activator inhibitor-1.
injury (Danenberg et al., 2003; Wang et al., 2005). Furthermore,
injection of highly purified CRP into humans activates the inflam-
mation and blood coagulation system (Bisoendial et al., 2007).
Therefore, CRP may trigger clinical ischemic events by promoting
thrombosis. The consequences of CRP and ROS in platelet acti-
vation and thrombus formation, as well as atherosclerosis, are key
features of atherothrombosis.
CONCLUSION
In summary, the presence of CRP in atherosclerotic lesions, likely
directly contributes to ROS generation in association with fam-
ily of FcγRs in platelets, and is linked to the regulation of
pro-thrombotic events, including activation of blood platelets,
the extrinsic blood coagulation cascade, and the fibrinolytic
system (Figure 1). ROS generation induced by CRP in vas-
cular cells is associated with the production of tissue factor.
Further studies are necessary to define more precisely the pro-
thrombotic functions of CRP-related ROS generation. In addi-
tion, more research is needed in order to determine if specif-
ically inhibiting CPR-modulated ROS would inhibit arterial
thrombosis.
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